Table I.
Association of molecular markers with clinical and pathologic characteristics of patients who were diagnosed with high-risk stage Ta T1 urothelial carcinoma of the bladder.
| E-cadherin | CAR | S100A4 | Uroplakin III | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
||||||||||
| Characteristics, n (%) | Patients | Normal | Abnormal | P-value | Normal | Abnormal | P-value | Normal | Abnormal | P-value | Normal | Abnormal | P-value |
| Total | 77 (100) | 65 (84) | 12 (16) | 64 (83) | 13 (17) | 56 (73) | 21 (27) | 30 (39) | 47 (61) | ||||
| Gender | >0.999 | 0.724 | >0.999 | 0.859 | |||||||||
| Male | 58 (75) | 49 (84) | 9 (16) | 49 (84) | 9 (16) | 43 (74) | 15 (26) | 24 (41) | 34 (59) | ||||
| Female | 19 (25) | 16 (84) | 3 (16) | 15 (79) | 4 (21) | 13 (68) | 6 (32) | 6 (32) | 13 (68) | ||||
| Clinical stage | >0.999 | 0.265 | 0.661 | >0.999 | |||||||||
| Ta | 6 (8) | 5 (83) | 1 (17) | 4 (67) | 2 (33) | 4 (67) | 2 (33) | 2 (33) | 4 (67) | ||||
| T1 | 71 (92) | 60 (85) | 11 (15) | 60 (85) | 11 (15) | 52 (73) | 19 (27) | 28 (39) | 43 (61) | ||||
| Size (cm) | >0.999 | 0.721 | 0.764 | 0.408 | |||||||||
| >1 | 59 (77) | 50 (85) | 9 (15) | 48 (81) | 11 (19) | 42 (71) | 17 (29) | 25 (42) | 34 (58) | ||||
| ≤1 | 18 (23) | 15 (83) | 3 (17) | 16 (89) | 2 (11) | 14 (78) | 4 (22) | 5 (28) | 13 (72) | ||||
| No. of tumors | >0.999 | 0.029 | 0.799 | 0.641 | |||||||||
| Single | 31 (40) | 26 (84) | 5 (16) | 22 (71) | 9 (29) | 22 (71) | 9 (29) | 11 (35) | 20 (65) | ||||
| Multiple | 46 (60) | 39 (85) | 7 (15) | 42 (91) | 4 (9) | 34 (74) | 12 (26) | 19 (39) | 27 (61) | ||||
| BCG therapy | >0.999 | 0.769 | 0.315 | 0.161 | |||||||||
| Yes | 44 (57) | 37 (84) | 7 (16) | 36 (82) | 8 (18) | 34 (77) | 10 (23) | 14 (32) | 30 (68) | ||||
| No | 33 (43) | 28 (85) | 5 (15) | 28 (85) | 5 (15) | 22 (67) | 11 (33) | 16 (48) | 17 (52) | ||||
P<0.05 was considered to indicate a statistically significant difference. BCG, bacillus Calmette-Guérin; CAR, coxsackie adenovirus receptor.